Despite rising sales driven by premium pricing, volumes of recently launched blockbuster drugs like Eli Lilly’s Mounjaro (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide) are falling, as India faces challenges in scaling next-generation anti-obesity therapies.

Eli Lilly’s Mounjaro has made a significant impact on India’s anti-diabetic and anti-obesity segment, posting ₹80.15 crore in sales in September 2025—a 43% jump from ₹56.01 crore in August, according to data released by market research firm Pharmarack. Since its March 2025 launch, cumulative revenue has reached ₹233.83 crore. The surge is powered by Lilly’s premium multi-dose KwikPen, which delivers more treatment cycles per unit at a higher price. Advertisement

According to Pharmarack, Mounjaro has become the second-largest b

See Full Page